Intrinsiqq
Lytix Biopharma ASA logo

Lytix Biopharma ASA Quality Score

LYTIX.XOSL

Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-0.6x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-6.9x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
93.9%

Heavy dilution above 5%

Capital Structure
100/100
-kr 69M

Net cash position, no leverage concern

2022
kr 144M
kr 1.00M
2023
kr 49.0M
kr 492000
2024
kr 129M
kr 3.00M
2025
kr 72.0M
kr 2.00M
CashDebt
Return on Capital
0/100
-58.0%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Lytix Biopharma ASA (LYTIX.XOSL) quality: score, margins and returns

Lytix Biopharma ASA (LYTIX.XOSL) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100 and -58.0% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Lytix Biopharma ASA (LYTIX.XOSL) a high-quality business?+

Lytix Biopharma ASA scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -58.0% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Lytix Biopharma ASA's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from LYTIX.XOSL's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Lytix Biopharma ASA scores well and where it falls behind.

What is Lytix Biopharma ASA's return on invested capital (ROIC)?+

Lytix Biopharma ASA earns about -58.0% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to LYTIX.XOSL's margins and growth on this scorecard to judge durability.

More on LYTIX.XOSL: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with LYTIX.XOSL

CompareIntrinsic value
SOFTX.XOSLSoftOx Solutions AS
€0.01+0.00%10
HBC.XOSLHofseth BioCare ASA
€0.09+0.00%30
NAVA.XOSLNavamedic ASA
€0.95-3.85%29
ONCIN.XOSLOncoinvent ASA
kr 72.20+7.12%50
ZLNA.XOSLZelluna ASA
€1.33-5.67%20
VISTN.XOSLVistin Pharma ASA
€1.76+0.57%81
PHO.XOSLPhotocure ASA
kr 40.85-2.85%88
OMDA.XOSLOmda A/S
€4.07-0.25%42

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing LYTIX.XOSL

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.